What Happened?
Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) jumped 24.1% in the afternoon session after positive earnings reports from industry peers lifted the entire contract research organization sector. The rally was sparked by strong second-quarter results from two major players in the space, IQVIA and Medpace, which both reported earnings and revenue that beat analyst expectations. Medpace, in particular, surged after significantly raising its full-year guidance for revenue and earnings. This wave of good news from competitors boosted investor confidence across the sector, leading to gains for other contract research organizations (CROs) like Fortrea. A CRO provides outsourced research and development services to the pharmaceutical and biotechnology industries. Fortrea is scheduled to report its own second-quarter financial results on August 6, 2025.
Is now the time to buy Fortrea? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Fortrea’s shares are extremely volatile and have had 53 moves greater than 5% over the last year. But moves this big are rare even for Fortrea and indicate this news significantly impacted the market’s perception of the business.
The previous big move we wrote about was 4 days ago when the stock dropped 9.2% as several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively.
Additionally, some pharmaceutical and biotech companies experienced sharp drops following unfavorable news; for instance, Sarepta Therapeutics plunged after a report indicated another patient death tied to its experimental gene therapy, and GSK's blood cancer drug dosage was voted against by the FDA advisory committee. Broader market sentiment, including concerns about rising costs and inadequate pricing for 2025 plans among health insurers, also contributed to the downward pressure on healthcare equities.
Fortrea is down 68.9% since the beginning of the year, and at $5.80 per share, it is trading 79.2% below its 52-week high of $27.88 from July 2024. Investors who bought $1,000 worth of Fortrea’s shares at the IPO in June 2023 would now be looking at an investment worth $192.69.
Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free and will only take you a second.